ValuEngine upgraded shares of Progenics Pharmaceuticals (NASDAQ:PGNX) from a sell rating to a hold rating in a research note released on Thursday morning.

PGNX has been the topic of a number of other research reports. Cantor Fitzgerald set a $15.00 price target on Progenics Pharmaceuticals and gave the stock a buy rating in a research report on Wednesday, August 9th. Needham & Company LLC reissued a strong-buy rating and set a $14.00 price target on shares of Progenics Pharmaceuticals in a research report on Friday, September 1st. Zacks Investment Research downgraded Progenics Pharmaceuticals from a hold rating to a sell rating in a research report on Wednesday, October 18th. Finally, Aegis reissued a buy rating and set a $14.00 price target on shares of Progenics Pharmaceuticals in a research report on Tuesday, August 22nd. One analyst has rated the stock with a sell rating, two have assigned a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. Progenics Pharmaceuticals currently has an average rating of Buy and a consensus target price of $13.75.

Progenics Pharmaceuticals (NASDAQ:PGNX) traded down $0.19 on Thursday, hitting $5.98. The stock had a trading volume of 310,717 shares, compared to its average volume of 1,068,392. Progenics Pharmaceuticals has a fifty-two week low of $4.60 and a fifty-two week high of $11.72. The company has a debt-to-equity ratio of 0.80, a quick ratio of 7.86 and a current ratio of 7.86.

Progenics Pharmaceuticals (NASDAQ:PGNX) last posted its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.02. Progenics Pharmaceuticals had a negative return on equity of 67.61% and a negative net margin of 445.81%. The business had revenue of $2.70 million for the quarter, compared to the consensus estimate of $3.58 million. During the same quarter in the prior year, the company earned $0.52 EPS. The business’s revenue was down 95.0% compared to the same quarter last year. equities analysts expect that Progenics Pharmaceuticals will post -0.92 EPS for the current year.

Several hedge funds and other institutional investors have recently modified their holdings of PGNX. Piedmont Investment Advisors LLC purchased a new stake in shares of Progenics Pharmaceuticals during the 2nd quarter worth $103,000. Los Angeles Capital Management & Equity Research Inc. purchased a new stake in shares of Progenics Pharmaceuticals during the 2nd quarter worth $108,000. Municipal Employees Retirement System of Michigan lifted its stake in shares of Progenics Pharmaceuticals by 4.0% during the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 16,600 shares of the biotechnology company’s stock worth $113,000 after purchasing an additional 640 shares during the last quarter. LS Investment Advisors LLC lifted its stake in shares of Progenics Pharmaceuticals by 473.8% during the 2nd quarter. LS Investment Advisors LLC now owns 16,897 shares of the biotechnology company’s stock worth $115,000 after purchasing an additional 13,952 shares during the last quarter. Finally, Aperio Group LLC purchased a new stake in shares of Progenics Pharmaceuticals during the 3rd quarter worth $118,000. Hedge funds and other institutional investors own 84.64% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Progenics Pharmaceuticals (PGNX) Upgraded at ValuEngine” was first published by Watch List News and is the property of of Watch List News. If you are viewing this piece on another domain, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be accessed at https://www.watchlistnews.com/progenics-pharmaceuticals-pgnx-upgraded-at-valuengine/1757646.html.

Progenics Pharmaceuticals Company Profile

Progenics Pharmaceuticals, Inc is engaged in developing medicines and other products for targeting and treating cancer. The Company’s pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Progenics Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.